Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030
Triton’s research report studies that the Latin American ophthalmic drugs market is anticipated to rise at 7.41% CAGR during the forecast period 2023-2030.
Report scope can be customized per your requirements - Request Free Sample Report
The countries examined in the studied region include:
•        Brazil
•        Mexico
•        Rest
of Latin America
Multiple
factors, such as expansion in healthcare infrastructure, an increase in the
number of eye disorders among the adult population, and awareness regarding eye
health drive the growth of the ophthalmic drugs market in Latin America. There is a significant rise in the use of ophthalmic
drug products to prevent blindness and vision impairment. The established
pharmaceutical companies, as well as new entrants, take the lead to develop a
streamlined ophthalmic drug delivery system and enhance treatment efficacy,
especially among the middle-class population.
Brazil leads with the highest
share in the Latin American ophthalmic drugs market. The regulatory
norms by the National Health Surveillance Agency (ANVISA) ensure
that ophthalmic drug products meet high quality and safety standards. Additionally,
the demographic transitions and developments in the healthcare sector propel
the growth of the ophthalmic drugs market. The use of these drugs is mainly due to
the rise in the aging population and their eye disorders.
In Mexico, the ophthalmic drugs market is also
experiencing innovation due to mergers and collaborations. This presents substantial
growth opportunities to develop eye care products that are safe and efficient.
The inventions and recent developments regarding eye therapies and cataract
treatments also drive the use of ophthalmic drugs. The government, therefore,
caters to the diverse eye care needs of the population by increasing the
expenditure on healthcare.
Since COVID-19, online pharmacies have been one of
the convenient channels for ophthalmic drug delivery systems. The growth of
such virtual platforms enables patients to get access to 24/7 treatment facilities
within the comfort of their homes, preventing high medication costs. The segments of the studied market include type, delivery
method, therapeutic type, condition, and channel. The channel type segment comprises Hospital Pharmacies, drugs, online pharmacies, and
other distribution channels.
The leading enterprises in the ophthalmic drugs
market are Bausch
Health Companies Inc, AbbVie Inc, Pfizer Inc, Sun Pharmaceutical Industries
Ltd, Johnson & Johnson, Thea
Pharma Inc, Novartis AG, Accutome Inc, Regeneron Pharmaceuticals Inc, and
Genentech Inc.
Bausch
Health Companies Inc is a pharmaceutical company based in Canada that
manufactures and develops both branded as wells as generic pharmaceutical
products. Its portfolio includes generics, neurology, dentistry,
gastrointestinal, dermatology products, international pharmaceuticals, etc. The
company markets its products across 90 countries across multiple regions,
including Latin America, Europe, Asia-Pacific, and Africa.
KEY
DELIVERABLES OF THE REPORT:
â—ŹÂ Â Â Â Â
Market CAGR during the forecasting years 2023-2030
â—ŹÂ Â Â Â Â
Detailed data highlighting key insights, industry components, and
market strategies
â—ŹÂ Â Â Â Â
Comprehensive information and estimation of the ophthalmic
drugs
market revenue growth in Latin America and its influence on the parent market
â—ŹÂ Â Â Â Â
In-depth study of forthcoming trends in consumer behavioral
patterns
â—ŹÂ Â Â Â Â
A meticulous analysis of the competitive landscape, vendor
scorecard, and Porter’s Five Forces
â—ŹÂ Â Â Â Â
A wide-ranging study of factors that will challenge the Latin
America ophthalmic drugs market’s growth during the upcoming
years
Want to get specific insights? Our team of
analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1.   LATIN
AMERICA OPHTHALMIC DRUGS MARKET - SUMMARY
2.   INDUSTRY
OUTLOOK
2.1. TECHNOLOGY
SNAPSHOT
2.2. IMPACT
ANALYSIS ON THE OPHTHALMIC DRUGS MARKET
2.2.1. COVID-19
IMPACT ON THE OPHTHALMIC DRUGS MARKET
2.3. PORTERS
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
MATURITY ANALYSIS
2.5. REGULATORY
FRAMEWORK
2.6. KEY
BUYING IMPACT ANALYSIS
2.7. KEY
MARKET STRATEGIES
2.7.1. COLLABORATIONS
2.7.2. PRODUCT
LAUNCHES
2.7.3. MERGERS
& ACQUISITIONS
2.8. MARKET
DRIVERS
2.8.1. AGING
POPULATION VULNERABLE TO EYE DISORDERS
2.8.2. PROGRESS
IN DRUG DELIVERY TECHNOLOGIES
2.8.3. ESCALATING
INCIDENCE OF OCULAR DISEASES
2.8.4. REIMBURSEMENT
POLICIES BY HEALTHCARE SYSTEMS
2.9. MARKET
CHALLENGES
2.9.1. CHALLENGING
TIMELINES FOR PRODUCT APPROVAL
2.9.2. ADVERSE
EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE
2.10. MARKET
OPPORTUNITIES
2.10.1. SURGE
IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS
2.10.2. INCREASE
IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES
2.11. ANALYST
PERSPECTIVE
3.   LATIN
AMERICA OPHTHALMIC DRUGS MARKET – BY TYPE
3.1. PRESCRIPTION
DRUGS
3.2. OVER-THE-COUNTER
DRUGS
4.   LATIN
AMERICA OPHTHALMIC DRUGS MARKET – BY CONDITION
4.1. DRY
EYE
4.2. GLAUCOMA
4.3. INFECTION/INFLAMMATION/ALLERGIES
4.4. RETINAL
DISORDER
4.4.1. WET-AGE
RELATED MACULAR DEGENERATION
4.4.2. DRY-AGE
RELATED MACULAR DEGENERATION
4.4.3. DIABETIC
RETINOPATHY
4.4.4. OTHER
RETINAL DISORDERS
4.5. OTHER
CONDITIONS
5.   LATIN
AMERICA OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE
5.1. ANTI-GLAUCOMA
5.2. ANTI-INFECTION
5.3. ANTI-INFLAMMATORY
5.4. ANTI-ALLERGY
5.5. OTHER
THERAPEUTIC TYPES
6.   LATIN
AMERICA OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD
6.1. GELS
6.2. EYE
SOLUTIONS & SUSPENSIONS
6.3. CAPSULES
& TABLETS
6.4. EYE
DROPS
6.5. OINTMENTS
7.   LATIN
AMERICA OPHTHALMIC DRUGS MARKET – BY CHANNEL
7.1. HOSPITAL
PHARMACIES
7.2. DRUG
STORES
7.3. ONLINE
PHARMACIES
7.4. OTHER
CHANNELS
8.   LATIN
AMERICA OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK
8.1. BRAZIL
8.1.1. BRAZIL
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2. MEXICO
8.2.1. MEXICO
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3. REST
OF LATIN AMERICA
8.3.1. REST
OF LATIN AMERICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
9.   COMPETITIVE
LANDSCAPE
9.1. ABBVIE
INC
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.1.3. KEY
STRENGTHS
9.1.4. KEY
CHALLENGES
9.2. BAUSCH
HEALTH COMPANIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY
CHALLENGES
9.3. JOHNSON
& JOHNSON
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY
STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. NOVARTIS
AG
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. REGENERON
PHARMACEUTICALS INC
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.5.3. KEY
STRENGTHS
9.5.4. KEY
CHALLENGES
9.6. SUN
PHARMACEUTICAL INDUSTRIES LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY
STRENGTHS
9.6.4. KEY
CHALLENGES
9.7. ACCUTOME
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY
STRENGTHS
9.7.4. KEY
CHALLENGES
9.8. GENENTECH
INC
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.8.3. KEY
STRENGTHS
9.8.4. KEY CHALLENGES
9.9. THEA
PHARMA INC
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.9.3. KEY
STRENGTHS
9.9.4. KEY
CHALLENGES
9.10. PFIZER
INC
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY
STRENGTHS
9.10.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2023-2030 (IN $ MILLION)
TABLE 2: REGULATORY
FRAMEWORK
TABLE 3: LIST OF
COLLABORATIONS
TABLE 4: LIST OF
PRODUCT LAUNCHES
TABLE 5: LIST OF
MERGERS & ACQUISITIONS
TABLE 6: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE 7: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)
TABLE 8: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)
TABLE 9: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)
TABLE 10: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)
TABLE 11: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)
TABLE 12: LATIN AMERICA
OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)
FIGURE 1: TECHNOLOGY SNAPSHOT
FIGURE 2: MARKET MATURITY ANALYSIS
FIGURE 3: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030
(IN %)
FIGURE 4: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS,
2023-2030 (IN $ MILLION)
FIGURE 5: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER
DRUGS, 2023-2030 (IN $ MILLION)
FIGURE 6: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 &
2030 (IN %)
FIGURE 7: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030
(IN $ MILLION)
FIGURE 8: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030
(IN $ MILLION)
FIGURE 9: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY
INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)
FIGURE 10: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2023-2030 (IN $ MILLION)
FIGURE 11: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2022 & 2030 (IN %)
FIGURE 12: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED
MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 13: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED
MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 14: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DIABETIC
RETINOPATHY, 2023-2030 (IN $ MILLION)
FIGURE 15: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL
DISORDERS, 2023-2030 (IN $ MILLION)
FIGURE 16: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS,
2023-2030 (IN $ MILLION)
FIGURE 17: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE,
2022 & 2030 (IN %)
FIGURE 18: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA,
2023-2030 (IN $ MILLION)
FIGURE 19: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION,
2023-2030 (IN $ MILLION)
FIGURE 20: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY,
2023-2030 (IN $ MILLION)
FIGURE 21: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY,
2023-2030 (IN $ MILLION)
FIGURE 22: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC
TYPES, 2023-2030 (IN $ MILLION)
FIGURE 23: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD,
2022 & 2030 (IN %)
FIGURE 24: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN
$ MILLION)
FIGURE 25: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS &
SUSPENSIONS, 2023-2030 (IN $ MILLION)
FIGURE 26: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CAPSULES &
TABLETS, 2023-2030 (IN $ MILLION)
FIGURE 27: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030
(IN $ MILLION)
FIGURE 28: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030
(IN $ MILLION)
FIGURE 29: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 &
2030 (IN %)
FIGURE 30: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 31: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DRUG STORES,
2023-2030 (IN $ MILLION)
FIGURE 32: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 33: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS,
2023-2030 (IN $ MILLION)
FIGURE 34: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK,
2022 & 2030 (IN %)
FIGURE 35: BRAZIL OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 36: MEXICO OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 37: REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $
MILLION)